Pneumonia

>

Latest News

Sanofi and SK Bioscience Expand Pneumococcal Vaccine Partnership, Launch Phase 3 Trial for PCV21 / Image credit: ©Crystal Light/AdobeStock
Sanofi and SK Bioscience Expand Pneumococcal Vaccine Partnership, Launch Phase 3 Trial for PCV21

January 6th 2025

Sanofi and SK bioscience expand collaboration on pneumococcal conjugate vaccines, including a 21-valent candidate for pediatric populations.

Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock
Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose

October 30th 2024

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 Years / image credit  ©CDC
ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 from 65 Years

October 24th 2024

ACIP Highlights Evidence Supporting Recommendation for PCV21 Vaccine for Adults / Image credit: ©Crystal Light/AdobeStock
ACIP Highlights Evidence Supporting Recommendation for PCV21 Vaccine for Adults

September 20th 2024

UPDATE: ACIP Vote Unanimous to Recommend Merck 21-Valent Pneumococcal Shot for Older Adults / image credit - pneumonia in alveoli: ©Kateryna Kon/stock.adobe.com
UPDATE: ACIP Vote Unanimous to Recommend Merck 21-Valent Pneumococcal Shot for Older Adults

July 1st 2024

© 2025 MJH Life Sciences

All rights reserved.